Navigation Links
Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
Date:1/6/2009

SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the JPMorgan Healthcare Conference in San Francisco on Monday, January 12, 2009 at 10:00 a.m. PT / 1:00 p.m. ET. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will be providing a corporate overview.

The live presentation and breakout session will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate

Web site, located at www.amylin.com. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
2. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
3. Lilly and Amylin Set Date and Time for Conference Call
4. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
5. Amylin Pharmaceuticals Reports First Quarter Financial Results
6. Amylin Pharmaceuticals Reports 2007 Financial Results
7. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
8. Amylin Pharmaceuticals to Present at Research & Development Day
9. Amylin Pharmaceuticals to Webcast Conference Call
10. Amylin Pharmaceuticals to Webcast Third Quarter Results
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... SALT LAKE CITY, UTAH (PRWEB) , ... April ... ... Josée Côté as Account Manager for the North East region. Côté has 20+ ... operations and consulting. Prior to Phytomer, Côté worked with an array of high-end ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor that has ... presence to an educational purpose as the host of the “Informed” series. The program ... a recent episode, the series focuses on thyroid cancer. , Although thyroid cancer is ...
(Date:4/27/2017)... , ... April 27, 2017 , ... ... Insights in Incentives, Rewards, and Recognition: A Nudge Guide," a groundbreaking analysis of ... field. Offering practical takeaways to apply immediately to IRR programs, the report highlights ...
(Date:4/27/2017)... Neb. (PRWEB) , ... April 27, 2017 , ... ... was named the 2017 North American CAREGiverSM of the Year for her extraordinary ... selects one of its 60,000 North American professional caregivers for the prestigious award ...
(Date:4/27/2017)... GA (PRWEB) , ... April 27, 2017 , ... Are ... a tragic spike in water-related accidents and drownings during the summer. While most of ... is that these situations occur every day. Very few people are taking the time ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)... April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) ... & Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... , Chief Executive Officer of the Company is scheduled to present ... Richard Bear and the Chairman of the Board, Tony ... ...
Breaking Medicine Technology: